(Total Views: 167)
Posted On: 10/30/2018 5:12:42 PM
Post# of 333
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Applauds DEA’s Removal of Certain CBD Products from Schedule 1 List of Controlled Substances
Biotechnology company Earth Science Tech (OTCQB: ETST) is set to gain from the U.S. Drug Enforcement Agency’s (“DEA”) recent decision to remove certain CBD products from its Schedule 1 list of controlled substances, making it easier to plan CBD clinical studies (http://nnw.fm/HXaY7). A recent article discussing the company’s stance on the decision reads, “The DEA decided to remove some CBD products from its Schedule 1 list of controlled substances. It voted to reclassify FDA-approved drugs that contain cannabis-derived CBD and contain less than 0.1% tetrahydrocannabinol (THC) as Schedule V, the lowest restriction classification. … ETST sees this ruling as an opportunity. In a news release, Dr. Michel Aubé, CEO and chief science officer of ETST, said, ‘In 2018, we have a much deeper understanding of cannabinoids, cannabinoid-receptors, and the endocannabinoid system than we did decades ago when CBD was classified as a schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company Earth Science Tech (OTCQB: ETST) is set to gain from the U.S. Drug Enforcement Agency’s (“DEA”) recent decision to remove certain CBD products from its Schedule 1 list of controlled substances, making it easier to plan CBD clinical studies (http://nnw.fm/HXaY7). A recent article discussing the company’s stance on the decision reads, “The DEA decided to remove some CBD products from its Schedule 1 list of controlled substances. It voted to reclassify FDA-approved drugs that contain cannabis-derived CBD and contain less than 0.1% tetrahydrocannabinol (THC) as Schedule V, the lowest restriction classification. … ETST sees this ruling as an opportunity. In a news release, Dr. Michel Aubé, CEO and chief science officer of ETST, said, ‘In 2018, we have a much deeper understanding of cannabinoids, cannabinoid-receptors, and the endocannabinoid system than we did decades ago when CBD was classified as a schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
